beta

AKTX

Akari Therapeutics Plc

Aktx

Chart

Stats

Earnings

News

Splits

Dividends

Earnings

Actual EPS
Consensus EPS
Estimated EPS
Number of Estimates
EPS Surprise

Stats

Summary

Akari Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics to treat orphan autoimmune and inflammatory diseases. Its lead product candidate, Nomacopan, is a second-generation complement inhibitor. The company was founded on October 7, 2004 and is headquartered in London, the United Kingdom.

Market Cap: 40.1 Million

Primary Exchange: NASDAQ

Website: http://akaritx.com

Shares Outstanding: 21 Million

Float: 20.6 Million

Dividend: (%)

Beta: 0.0270664071260887

Sector: Health Technology

Industry: Pharmaceuticals: Major

Ethical Flags

Animal testing

Longest drawdown: 1981 trading days

From: 2014-01-15 To: 2019-12-09

Lowest Point:

Ex-Date Payment Date Record Date Declared Date Amount Flag Dividend Type Qualified Indicated
Ex-Date Declared Date Record Date Payment Date Ratio To Factor For Factor
2015-09-17 10.0 1.0 10.0
Data provided by IEX Cloud